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Abstract 
Background: There is currently a lack of reliable, minimally invasive biomarkers that could predict the extent of 
alcoholism‑induced CNS damage. Developing such biomarkers may prove useful in reducing the prevalence of 
alcohol use disorders (AUDs). Extracellular microRNAs (miRNAs) can be informative molecular indicators of changes 
in neuronal gene expression. In this study, we performed a global analysis of extracellular miRNAs to identify robust 
biomarkers of early CNS damage in humans diagnosed with DSM‑IV AUDs. We recruited a relatively young set of 20 
AUD subjects and 10 age‑matched controls. They were subjected to comprehensive medical, neuropsychological and 
neuroimaging tests, followed by comparison of miRNA levels found in peripheral blood serum. Employing a conserva‑
tive strategy to identify candidate biomarkers, miRNAs were quantified using two independent high‑throughput 
methods: microarray and next‑generation RNA‑sequencing. This improved our capacity to discover and validate 
relevant miRNAs.
Results: Our results identified several miRNAs with significant and reproducible expression changes in AUD subjects 
versus controls. Moreover, several significant associations between candidate miRNA biomarkers and various medical, 
neuropsychological and neuroimaging parameters were identified using Pearson correlation and unbiased hierarchi‑
cal clustering analyses. Some of the top candidate biomarkers identified, such as mir‑92b and mir‑96 have established 
roles in neural development. Cross‑species validation of miRNA expression was performed using two different in vivo 
rat drinking models and two different in vitro mouse neural stem cell exposure models. A systems level analysis 
revealed a remarkable degree of convergence in the top changes seen in all of these data sets, specifically identifying 
cell death, cell proliferation and cell cycle processes as most consistently affected. Though not necessarily the same 
molecules, the affected miRNAs within these pathways clearly influence common genes, such as p53 and TNF, which 
stand out as potential keystone molecules. Lastly, we also examined the potential tissue origins of these biomarkers 
by quantifying their levels in 15 different tissue types and show that several are highly‑enriched in the brain.
Conclusions: Collectively, our results suggest that serum miRNA expression changes can directly relate to alterations 
in CNS structure and function, and may do so through effects on highly specific cellular pathways.
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Background
Alcohol use disorders (AUDs) are a major public health 
problem and impose a substantial socioeconomic bur-
den. In the US alone, there is a one in seven lifetime 
prevalence of AUD [1]. Structural brain damage and the 
widespread alteration of neuronal function that accom-
panies it represent two of the most adverse effects of 
AUDs (recently reviewed in [2]). However, despite well-
documented effects on the CNS, there are no definitive 
molecular signatures of AUD-induced brain damage. 
This limits the selection of rational interventions and 
hampers the ability to gauge therapeutic effects. Thus, 
developing biomarkers that indicate early CNS damage 
may prove useful in deterring the emergence of AUDs.
We recently completed an extensive messenger RNA 
(mRNA) expression-based study of human subjects with 
AUDs as well as adolescent and adult rats engaged in 
excessive alcohol consumption and mouse neural stem 
cells (NSCs) exposed to ethanol in vitro [3]. In that study, 
we sought to identify mRNA biomarkers in peripheral 
blood leukocytes (PBLs) that could predict CNS dysfunc-
tion related to excessive alcohol consumption across dif-
ferent species and models. Based on pre-existing data, 
we chose to test only a specific set of mRNAs with func-
tions related to cell cycle regulation, DNA damage and 
repair, as well as p53 signaling. We found that a subset 
of the tested mRNAs was consistently changed in human 
AUD subjects, ethanol-consuming rats, and ethanol-
exposed NSCs. Moreover, several of the affected mRNAs 
showed robust correlations with different biological vari-
ables, including neuroimaging volumes, neuropsycho-
logical performance scores, as well as indices of ethanol 
consumption.
Despite promising leads from our focused mRNA 
study, there were a number of limitations on its over-
all potential utility. First, because we examined expres-
sion of mRNA from the PBLs of our AUD subjects, we 
could only speculate about potential transcript changes 
in other tissues, such as the brain. Second, many subjects 
in that study had long histories of AUD, and therefore 
did not represent an optimal subject set for discovering 
markers of early AUD-induced alterations, which could 
potentially be reversible. Third, the analysis we per-
formed was focused exclusively on a limited set of a few 
hundred mRNAs that had been identified through pre-
vious screens [4] rather than the entire transcriptome. 
Finally, the alterations in brain volumes we observed in 
the previous study were not controlled for overall brain 
shrinkage, which is well-characterized in AUDs as well as 
advanced aging.
Because of the limitations just described, in the present 
study, we sought to expand upon our previous work by 
examining whether we could identify even more robust 
biomarkers using: (1) a younger subset of AUD subjects 
with shorter histories of alcohol consumption who were 
completely age-matched to controls; (2) neuroimaging 
measures that were normalized to whole-brain volumes; 
and (3) measurements of extracellular microRNAs (miR-
NAs) rather than leukocyte mRNA for detection of early 
stage CNS damage.
Our current focus on miRNAs builds upon consider-
able recent interest in their potential use as biomarkers 
in other diseases and conditions. MicroRNAs are short, 
hairpin-derived RNAs that repress protein expression of 
a large fraction of the genome in a vast array of species. 
In mammals, approximately half of all mRNAs maintain 
selective pairing with miRNAs [5]. Thus, miRNAs have 
emerged as a class of master regulatory molecules that 
control the level of post-transcriptional gene expression. 
In neurons, miRNAs not only regulate mRNA levels, but 
they also compartmentalize specific mRNA expression 
within subcellular regions such as axons and dendrites 
[6].
Dysregulation of brain miRNAs have also been recently 
associated with alcohol exposure. In human post-mor-
tem brain samples, robust changes in miRNA expression 
have been reported in the prefrontal cortex of subjects 
with a history of chronic alcohol abuse compared to con-
trols [7]. Robust changes in miRNA levels have also been 
reported in the brains of rats following alcohol intoxica-
tion [8]. These findings are further supported by in vitro 
studies of the effects of ethanol effects on miRNA levels 
in neurosphere cultures [9].
In addition to their intracellular roles, miRNAs are 
released by normal and damaged cells into the blood-
stream and can serve as conduits for the spread of genetic 
and pathological information to distant cells and tissues. 
In this manner, miRNAs have been shown to mediate the 
spread of cell and tissue damage or alter the microenvi-
ronment [10]. In fact, brain-specific miRNAs have been 
identified in the blood and other bodily fluids and it has 
been suggested that they may provide the opportunity to 
evaluate ongoing changes in the CNS upon the initiation 
of neurodegeneration [11]. For example, in Alzheimer’s 
disease, miRNAs that are associated with neuropatho-
logical changes in post-mortem brain tissue have been 
detected in blood sera of subjects meeting ante-mortem 
criteria for the disease, albeit at lower basal levels [12]. 
The potential importance of such findings gains further 
support from a recent study that demonstrated serum 
mRNA levels could be directly regulated by brain-spe-
cific administration of RNAi [13].
In this study, we compared miRNA expression levels 
in the serum of human subjects diagnosed with AUDs 
to those in healthy control subjects in order to identify 
potential biomarkers of CNS alterations. Further, we 
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explored the potential relationship of candidate bio-
markers with various medical, neuropsychological and 
normalized neuroimaging data. Cross-species validation 
through miRNA profiling of various in vivo and in vitro 
ethanol exposure paradigms helped confirm key miRNA 
molecules affected by ethanol and their mRNA targets. 
Taken together, our data provide striking new insight into 
the potential epigenetic regulation of CNS gene expres-
sion alterations brought about by AUDs.
Results and discussion
In this study, we determined the feasibility of using serum 
miRNAs to predict the extent of structural and func-
tional CNS impairments associated with alcohol use dis-
orders. The subjects recruited for this study were selected 
to reflect the same average age and an equal number of 
males and females in each group (Table 1). Compared to 
our previous study that explored the use of mRNA pro-
files from peripheral blood leukocytes [3], the current 
study focused on a younger group of individuals, allow-
ing exploration of potentially more sensitive biomarkers 
of early CNS alterations. Such early detection could pro-
mote development of therapeutic and preventative inter-
ventions that might halt or potentially reverse the CNS 
effects.
On average our AUD subjects had been drinking an 
average of 12  years, starting around age 18. They drank 
alcohol an average of 15 days during the month prior to 
recruitment, and consumed approximately five drinks 
per drinking day. As a group, the AUD subjects had an 
average of one heavy drinking day (i.e. more than five 
drinks for men or four drinks for women) during the 
week prior to recruitment.
AUD subjects show changes in specific brain regions, 
and a subset of clinical, medical and neuropsychological 
measures
Comprehensive demographic, medical, neuropsychologi-
cal and neuroimaging data were collected from each of 
the subjects. Prior to hypothesis testing, variables were 
examined for equality of variance in AUD subjects and 
controls using a Fisher’s F test. Variables that passed 
the F test (p-value > 0.05) were examined for differences 
between AUD subjects and controls using a Student’s 
T-test, while those with unequal variance were tested 
using a Welch’s T-test. Unless otherwise stated, we did 
not correct for multiple testing due to the relatively small 
sample size and the desire to identify as many potential 
biomarkers as possible in our initial parametric screen. 
These were subsequently examined for quantitative asso-
ciations with the other variables of interest.
AUD subjects show elevations in GGT
Our statistical screen identified a relatively small set of 
variables that differed between AUD subjects and con-
trols (Table  2). Among the standard medical laboratory 
blood tests (including several that assess liver function), 
only the gamma-glutamyl transferase (GGT) assay dif-
fered between AUD and control subjects, with an average 
increase of 85 %. Notably, the average level in AUD sub-
jects was 37.4 IU/L, which is above the normal range for 
males and females of the same age as our subjects. These 
elevated levels suggest at least some amount of early liver 
damage may be occurring in our subjects, since GGT 
elevations are commonly seen in patients with alcoholic 
liver disease, a well-documented effect of chronic alcohol 
consumption.
AUD subjects show reductions in verbal fluency
Despite the large number of neuropsychological tests 
administered, AUD subjects only showed significant dif-
ferences compared to controls in the Letter Fluency Test 
of the Delis-Kaplan Executive Function System (D-KEFS) 
[14]. This test examines the ability to rapidly generate 
non-redundant words that begin with specific letters in a 
short time interval. The AUD subjects scored 22 % worse 
on average than controls in their scaled scores, indicat-
ing a relative impairment of a specific language function. 
Table 1 Human subject characteristics
AUD and control subject demographics. Both groups reflect the same average age. Subjects with alcohol use disorders were diagnosed using the DSM-IV alcohol 
abuse and dependence diagnostic criteria. A heavy drinking day was defined as 4 standard drinks for women and 5 for men
Control (n = 10) AUD (n = 20) DSM-IV diagnosis
AA (n = 4) AD (n = 16)
Gender 5F, 5M 10F, 10M 2F, 2M 8F, 8M
Age (years) 30.9 30.9 26.8 31.9
Drinking days last month – 15.3 15.25 15.31
Drinks/drinking day – 5.1 4 5.4
Heavy drinking days last week – 1.2 1 1.25
Age at onset – 18.6 19.5 18.3
Years drinking – 12.4 7.25 13.6
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This observation is consistent with significant verbal flu-
ency abnormalities that have been reported in patients 
with much longer histories of alcohol use disorders, 
including those with Korsakoff syndrome, a severe neu-
rologic complication of AUD [15].
The subtlety and specificity of our neuropsychological 
findings may reflect the younger average age of our sub-
jects, where alcohol-related brain damage phenotypes 
are more difficult to detect. Comparisons of our results 
are most appropriately made to neuropsychological stud-
ies of adolescent and young adult drinkers. Letter flu-
ency tests on university age (18–20 years) subjects have 
not found differences in performance when binge drink-
ers were compared to non-binge drinkers [16]. However, 
longer-term studies on adolescent alcohol abusers (13–
19  years, followed up after 4  years) have displayed sig-
nificantly impaired language skills [17]. This suggests that 
the language impairment we observed manifests itself 
later in young adulthood since our AUD subjects typi-
cally started drinking during adolescence (average onset 
of drinking age: 18.6  years). Indeed, our AUD subjects 
showed a significant correlation between Letter Fluency 
Test score and the number of years drinking (R = −0.46, 
p  <  0.05). Although the number of years drinking was 
confounded with age in our AUD subjects, we did not 
observe a significant association between age and Letter 
Fluency Test score in our controls.
AUD subjects exhibit overall loss of gray matter and increased 
sulcal size
Screening for possible structural brain changes in AUD 
subjects versus controls was initially performed using a 
combination of two different autothresholding meth-
ods on skull-stripped 3D reconstructions of MRI data 
(Fig.  1a). The moments method [18] created a binary 
image which excluded the sulci while the triangle method 
[19] created a binary image that included sulci and thus 
encompassed the entire visible external brain surface. 
The difference between these two images indicated the 
percentage of visible surface area occupied by cortical 
Table 2 Medical, neuropsychological, and neuroimaging variables with significant changes in AUD subjects
Comparison of various clinical and imaging parameters between AUD and control subjects. Neuroimaging measurements were normalized to whole brain size to 
correct for overall brain shrinkage before calculating  % changes relative to values from controls
a Indicates variables determined to have unequal variances using the Fisher’s F test that were examined for differences between groups using the Welch’s T-test. All 
other variables were evaluated using the Student’s T-test
Variable % Δ AUD T-test p-value Equality of variance
Medical
 Gamma‑glutamyl transferasea 84.9 0.040 0.001
Neuropsychological
 Letter fluency scorea −21.8 0.017 0.035
Normalized neuroimaging volumes
 Cerebrospinal fluid 31.7 0.005 –
 Anterior corpus callosum −14.6 0.008 –
 Left temporal superiorlateral gyrus −10.4 0.010 –
 Left ventral diencephalon 6.9 0.011 –
 Left central sulcus 16.7 0.012 –
 Left cingulomarginal sulcus −11.9 0.015 –
 Right temporal superiorlateral gyrus −10.7 0.019 –
 Right pars orbitalis white matter 13.3 0.024 –
 Left inferior occipital gyrus and sulcus −14.9 0.026 –
 Left superior temporal cortex −7.0 0.027 –
 Right anterior collateral transverse sulcus −15.4 0.032 –
 Left Brodmann’s area 3a 12.7 0.032 –
 Left superior frontal cortex 8.0 0.038 –
 3rd ventricle 22.3 0.039 –
 Right intraparietal and posterior transverse sulcus −10.3 0.041 –
 Right pars opercularis −13.2 0.043 –
 Right superior parietal cortex −8.4 0.043 –
 Left inferior frontal triangular gyrus −16.0 0.044 –
 Right inferior parietal cortex −7.7 0.049 –
 Right cingulomarginal sulcus −8.4 0.050 –
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sulci (Fig.  1b). A Student’s T-test performed on these 
measurements indicated significantly larger sulcal size 
(16 %, p = 0.017) in AUD subjects (Fig. 1c).
AUD subjects exhibit volumetric changes in multiple brain 
regions
Having observed an increased sulcal size even in this rel-
atively young cohort of AUD subjects, we further exam-
ined possible differences in regional brain volumes using 
a comprehensive unbiased approach to measure more 
than 360 pre-defined brain regions with the FreeSurfer 
software suite [Reviewed in 20]. Moreover, in contrast to 
our previous volumetric analysis of older AUD subjects 
and controls [3], we normalized all of these measure-
ments to total brain volume in order to control for overall 
brain shrinkage that occurs with AUD or aging. In this 
manner, we hoped to find changes indicative of enhanced 
vulnerability to AUD in some brain regions in a younger 
cohort. The subsequent comparisons between AUD and 
control subjects yielded 20 individual regions with vol-
umes that differed between groups (Table  2). Notably, 
because of our normalization method, the magnitude of 
changes in these 20 regions can be considered greater 
than that of the entire brain.
Consistent with our initial sulcal measurements, 
the FreeSurfer-based volumetric analysis supported 
Fig. 1 Subjects with alcohol use disorders have increased sulcal size. a Skull‑stripped brain reconstructions show increased sulcal size in subjects 
with AUDs when compared to age‑ and gender‑matched controls. b Sulcal size was measured in each reconstruction and expressed as a percent‑
age of the brain’s area. c Plot of mean sulcal size in AUD and control subjects (±SEM). Group differences in % sulci between subjects with AUDs and 
controls were determined using a Student’s T‑test. Y years of age
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widening of the left central sulcus as well as ventricular 
enlargement in the 3rd and 4th ventricles and an increase 
in total CSF volume. Four out of the seven regions repre-
senting ventricular and CSF spaces as well as sulci were 
larger in our AUD subjects. These findings support pre-
vious research showing greater than normal ventricular 
enlargement and sulcal widening in relation to increasing 
age [21] as well as CSF size [22].
Most of the remaining regional volumes showed 
a decrease in AUD subjects, consistent with their 
enhanced shrinkage relative to overall brain volume 
reduction. Indeed, alcohol-related brain damage (ARBD) 
has been well documented and does demonstrate some 
regional specificity, although some of these changes may 
be reversible by abstinence [Reviewed in 23]. Examples of 
such regions include the anterior corpus callosum, which 
we observed to be almost 15 % smaller in our AUD sub-
jects, consistent with a previous study of male [24] and 
female alcoholics [25]. Notably, however, the average ages 
of participants in the studies from that group (Males: 
48.8 ± 10.7 years; Females: 40.9 ± 9.6 years), were a dec-
ade older than our subjects (30.9 ± 10.2 years), suggest-
ing that corpus callosum volume shrinkage is occurring 
earlier than previously thought.
Global, high-throughput human miRNA expression 
screening and verification
To ensure optimal sampling, we employed a conserva-
tive strategy to identify and verify potential miRNA 
biomarkers Quantification of miRNAs were based pri-
marily on next-generation small RNA-sequencing (RNA-
Seq), which has emerged as a highly accurate method of 
miRNA quantification owing to its sensitivity and consid-
erable dynamic range [26].
To validate our RNA-Seq findings, and help reduce 
the type I (false positive) error rate, we used Affym-
etrix miRNA GeneChips as a complementary analysis. 
The combined application of these two technologies 
improved our capacity to discover AUD-relevant miR-
NAs that would have been overlooked had a single 
quantification method been employed. Indeed, we have 
recently used and discussed the merits of this combined 
approach in our studies of miRNA changes in adolescent 
rat brain following fetal alcohol exposures [27].
Most miRNAs in serum are present in fully mature ‑5p or ‑3p 
forms
Initial serum miRNA quantification was performed by 
aligning the Illumina RNA-Seq data to the hg19 human 
reference genome. This was performed because most 
miRNAs are encoded in intergenic regions, within non-
coding RNA genes or the introns of protein-coding 
genes. These primary miRNA transcripts (pri-miRNAs) 
are transcribed and processed in the nucleus before being 
exported out of the nucleus in their precursor hairpin 
forms (pre-miRNA). Further processing in the cytoplasm 
via the protein Dicer creates mature single-stranded 
miRNAs of approximately 20 nucleotides. These mature 
miRNAs then assemble into an RNA-induced silencing 
complex (RISC) that interacts with complementary mes-
senger RNAs, and either target them for degradation or 
interfere with translation efficiency [Reviewed in 28].
After whole genome alignment, we quantified reads 
using the RefSeq transcript annotation database and 
miRBase, an established, high-confidence database of 
microRNAs [29]. The latter quantified both precursor 
and mature miRNA regions. Inspection of our aligned 
reads against mature and precursor miRNA gene regions 
demonstrated that most reads were highly concentrated 
in one of two regions, corresponding to the mature -5p 
or -3p regions of individual miRNAs, with very few reads 
mapping to the flanking or internal sequence regions that 
would be derived from immature pre-miRNA or pri-
miRNA alignments (Represented by Fig.  2a). Indeed, a 
probe trend plot of all 1871 primary miRNA transcripts 
available in miRBase 20 showed a striking bimodal dis-
tribution (Fig. 2b), and strongly suggested that the major-
ity of miRNAs we quantified in serum were present in a 
mature (i.e., fully processed and possibly bioactive) form. 
Moreover, while the absolute levels of some miRNAs did 
appear to differ between subject groups, the overall pat-
tern of preference for -5p or -3p mature forms was highly 
similar.
A tier system for classifying between‑group differences 
across platforms
After alignment, we used the same statistical testing 
method described for the medical, demographic and 
neuroimaging variables to compare the miRNA lev-
els between subject groups for both the RNA-Seq and 
microarray data sets. Individual miRNAs with were then 
assigned to two different classification tiers depend-
ing on the strength of evidence for concordant changes 
in gene expression across the two quantification plat-
forms (Table  3). Because of the greater sensitivity and 
dynamic range of RNA-Seq, the values produced using 
this method formed the primary basis for comparison of 
the subject groups, with differences detected through the 
microarrays serving as a means of cross-platform valida-
tion. Tier A molecules represented stringent, nominally 
significant (p < 0.05) miRNAs generated from RNA-Seq 
quantification that also showed a strong trend (p < 0.10) 
and directionally consistent changes in the microarray 
experiments. Tier B molecules represented nominally 
significant (p  <  0.05) miRNAs as determined by RNA-
Seq that showed similar directional changes in the array 
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data regardless of the p value. When possible, the mature 
forms of the miRNAs were listed within each Tier (these 
contain a capital R in miR- and a -3p or -5p in the title, 
according to established convention). Notably, for miR-
NAs in Tiers A and B, the overall correlation in the per-
cent changes seen in AUD subjects with microarrays and 
RNA-Seq was 0.588 (p < 0.017).
Most changed miRNAs are increased in AUD serum
Examination of the miRNAs that were most robustly 
changed in our AUD subjects indicated that most were 
increased in expression (Table  3). This observation is 
consistent with miRNA findings in post-mortem brains 
of human alcoholics [7]. Thus, the increased miRNA we 
detected in AUD subjects suggests a possible compen-
satory mechanism for neuronal injury, or potentially 
even enhanced transport of miRNAs from the brain to 
the periphery as a result of cell damage. Similar findings 
for other neurodegenerative conditions such as trau-
matic brain injury have also been reported [30]. A total 
of 3 miRNAs in Tier A and 13 in Tier B were identified 
(Table  3). Interestingly, several of these miRNAs have 
been previously found to be present at abnormal levels 
in studies of post-mortem human alcoholic brain tissue 
and animal models of ethanol exposure. For example, 
we found evidence of decreased mir-92b and increased 
mir-96, mir-24, and mir-136 in our AUD subjects, con-
sistent with studies of primary cortical neurons [31], 
mouse frontal cortex [32] and rat ventral striatum [27, 
33]. Moreover, some of the miRNAs that we observed to 
change in the serum of AUD subjects were also shown to 
change in the same direction in studies of hepatocytes 
from mice with alcoholic liver damage (mir-127; see [34]) 
or whole zebrafish embryos exposed to alcohol (mir-24; 
see [35]).
On the other hand, we also observed some changes 
in the serum of AUD subjects that were opposite those 
reported in other studies. For example, we observed 
decreased expression of mir-301 (Tier B; Table 3), while 
other studies have shown increased levels in various 
brain regions after alcohol exposure. This includes our 
own findings in the amygdala [27] of prenatally-exposed 
Fig. 2 MicroRNAs in serum are in mature form. a Representative image showing RNA‑seq reads aligned to region on chromosome 13. Reads are 
concentrated on mature miRNA chromosome coordinates as defined by the miRBase 20 database. b Trend plots mapping reads across all precursor 
miRNAs in the human genome show that reads are concentrated in regions that roughly correspond to mature miRNAs (‑5p or ‑3p regions). We 
point out that the data shown are merely illustrative of the alignments produced during analysis of the RNA‑Seq reads. Note that mature miRNAs 
are derived from the same strand as the full‑length precursor, and appear in the location specified by the ‑5p box or ‑3p box. Also note that while 
the absolute levels of some mature miRNAs appeared to differ between AUD and Control subjects, the pattern of ‑5p or ‑3p usage appeared to be 
highly similar, which is best appreciated for the entire set of data in the lower plot
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rats, as well as the prefrontal cortex [8, 32] of postnatally-
exposed mice, and the frontal cortex from post-mortem 
brains of human alcoholics [7]. Such discrepancies could 
merely reflect the variability of different tissues being 
analyzed, but it is also possible that the levels reported 
in those studies are greatly influenced by intracellular 
miRNA processing, whereas the present data are derived 
from more stable extracellular serum miRNAs.
One miRNA finding of particular interest is mir-30a, 
which we observed to be increased 94  % in AUD sub-
jects (Tier B; Table  3). Although mir-30 was found to 
be decreased in whole embryos after ethanol exposure 
[35], it has been consistently shown to be increased in 
the brain of various models of ethanol exposure includ-
ing whole brain [36], nucleus accumbens [33] and fron-
tal cortex [32, 37]. Moreover, through its regulation of 
BDNF expression, mir-30a overexpression in the frontal 
cortex has also been shown to promote excessive alco-
hol intake which can then be reversed by inhibition of 
miRNA activity [37].
Association of serum miRNA levels 
with neuropsychological, demographic and neuroimaging 
variables identifies a third tier of miRNAs
We integrated our clinical and miRNA expression data-
sets to identify potentially relevant associations which 
could be further explored as indicators of AUD. This was 
examined using a Pearson correlation analysis to com-
pare miRNA expression levels and nominally significant 
neuropsychological, medical and neuroimaging measure-
ments. These comparisons specifically did not include 
correlations between brain regions or between miRNA 
levels, which would be very strong, but not particularly 
informative for this purpose. Notably, indices of alcohol 
consumption were only included in the association test-
ing of AUD subjects (since our control subjects did not 
drink) in an effort to identify direct biomarkers of alcohol 
consumption. Pearson correlations were used to calcu-
late T-scores and corresponding P-values. Variables that 
were changed in our parametric analyses (Tables  2, 3) 
were not corrected for multiple testing when evaluating 
their correlations. The results of this association testing 
are shown in Table 4. We also performed an exploratory 
screen of all expressed miRNAs against all other variables 
in order to detect associations in the AUD subjects that 
may have eluded detection in the parametric two group 
comparison. These correlations were not guided by any 
predictions about possible directional differences and 
thus were corrected for multiple testing using the Ben-
jamini-Hochberg False Discovery Rate (FDR) algorithm. 
Variables with an FDR <0.05 in the AUD subjects were 
defined as Tier C miRNAs and displayed along with the 
Table 3 Most consistently changed miRNAs in AUD
RNA-sequencing of human serum samples determined miRNAs with nominally significant alterations and trends in patients with AUDs. Comparison with microarray 
data subsequently identified changes that were consistent across platforms. MicroRNAs were classified into two tiers based on concurrence of both analyses. Where 
available, microRNA families for each miRNA are also listed. Note that these are nominal (uncorrected) p values
RPM normalized reads per million
Symbol RNA-seq Microarray
miRBase acc# miRBase family MiRBase fam acc # Ctrl RPM AUD RPM % Δ AUD P-value % Δ AUD P-value
Tier A: RNA‑seq p < 0.05, Array p < 0.1, consistent % Δ AUD
 mir‑96 MI0000098 mir‑96 MIPF0000072 4.6 11.3 142.6 0.031 15.0 0.059
 mir‑320b‑1 MI0003776 mir‑320 MIPF0000163 61.0 144.6 137.1 0.004 22.2 0.071
 mir‑1976 MI0009986 mir‑1976 MIPF0001633 4.1 9.9 138.1 0.039 24.1 0.081
Tier B: RNA‑seq p < 0.05, consistent % Δ AUD
 mir‑24‑1 MI0000080 mir‑24 MIPF0000041 31.3 90.5 189.4 0.008 6.2 0.338
 mir‑30a MI0000088 mir‑30 MIPF0000005 108.2 209.9 94.0 0.014 5.1 0.860
 mir‑92b MI0003560 mir‑25 MIPF0000013 7141.9 4553.8 −36.2 0.016 −8.2 0.312
 miR‑96‑5p MIMAT0000095 mir‑96 MIPF0000072 111.7 252.0 125.5 0.018 8.0 0.455
 mir‑127 MI0000472 mir‑127 MIPF0000080 68.6 158.9 131.5 0.021 8.4 0.455
 mir‑136 MI0000475 mir‑136 MIPF0000099 4.4 9.7 121.2 0.035 1.5 0.760
 miR‑301a‑3p MIMAT0000688 mir‑130 MIPF0000034 205.9 85.1 −58.7 0.045 −2.4 0.878
 mir‑320b‑2 MI0003839 mir‑320 MIPF0000163 61.3 148.8 142.9 0.004 5.2 0.333
 mir‑421 MI0003685 mir‑95 MIPF0000098 15.5 30.3 95.6 0.020 9.0 0.725
 miR‑660‑5p MIMAT0003338 mir‑188 MIPF0000113 196.9 99.7 −49.4 0.028 −10.2 0.451
 mir‑671 MI0003760 mir‑671 MIPF0000358 14.8 44.4 200.0 0.003 4.2 0.692
 mir‑3615 MI0016005 mir‑3615 MIPF0001540 50.1 78.3 56.4 0.031 1.3 0.881
 mir‑3676 MI0016077 2.1 11.1 437.1 0.027 12.9 0.218
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R, P, and FDR values observed in the Control subjects 
and combined subject groups (Table 5).
miRNAs are associated with inferior frontal lobe, 
neuropsychological performance, drinking parameters 
and blood pressure
Many significant correlations found with miRNAs in 
Tiers A, B and C were observed with distinct regions of 
the brain, including those that have already been iden-
tified as primarily decreased in alcoholics, such as the 
left inferior frontal triangular gyrus (mir-24-1, mir-136, 
mir-1976) and a similar region in the right inferior fron-
tal lobe along the pars opercularis (mir-24-1, mir-136). 
Notably, these two regions of the inferior frontal lobe are 
both involved in language function, and communicate 
with each other via the anterior corpus callosum, which 
we observed to be decreased in these same AUD subjects 
(Table 2). None of these particular miRNAs showed sig-
nificant correlations with Letter Fluency Score. However, 
one miRNA (miR-301a-3p) did exhibit significant cor-
relations with Letter Fluency Score and a region of the 
anterior inferior temporal lobe (the right anterior col-
lateral transverse sulcus), although the functions of this 
cortical area are unclear at this time. The exploratory cor-
relation analysis also identified some notable associations 
between miRNA levels and some of the drinking parame-
ters (let-7a-5p, mir-93, miR-139-5p, miR-1180-3p), blood 
pressure (mir-664), and brain areas involved in higher 
order visual, sensory, and limbic processing (mir-584-5p, 
mir-378a, mir-192-5p, mir-4433; Table 5).
In addition to the correlational analyses of individual 
miRNAs and variables, we also used MEV4 software [38] 
to perform a hierarchical cluster analysis and identify 
patterns of correlations between sets of variables across 
subjects (Fig.  3). The Pearson clustering algorithm with 
average linkage distances was employed for this because 
it most effectively distinguished AUD and control sub-
jects (Fig. 3, horizontal dashed line).
The clusters derived from this analysis, composed of 
mixed variable and miRNA components, provide addi-
tional insight into possible roles miRNAs play in the phe-
notypic changes we observe in AUD. For example, one 
Table 4 Variables correlated with Tiers A or B miRNAs in AUD subjects (p < 0.05)
Pearson correlation analysis of miRNA expression levels in AUD subjects reveal significant relationships between specific miRNA expression levels and other medical, 
drinking and neuroimaging variables that were significantly different in AUD subjects
R Pearson correlation coefficient, N number of pairs used in the calculation
miRNA Variable AUD Ctrl All
R P-value N R P-value N R P-value
In Tiers A and B
 miR‑660‑5p Drinking days last month 0.626 0.030 6
 mir‑421 Drinking days last week 0.482 0.020 12
 mir‑320b‑1 Drinks per drinking day 0.599 0.007 15
 mir‑320b‑2 Drinks per drinking day 0.934 0.002 15
 mir‑24‑1 Gamma‑glutamyl transferase 0.448 0.034 16 −0.558 0.276 9 0.312 0.084
 mir‑92b Gamma‑glutamyl transferase 0.691 0.005 17 0.306 0.329 10 0.173 0.350
 mir‑421 Gamma‑glutamyl transferase 0.476 0.022 14 −0.396 0.404 9 −0.024 0.914
 mir‑671 Gamma‑glutamyl transferase 0.594 0.043 16 −0.016 0.968 9 0.538 0.001
 mir‑1976 Gamma‑glutamyl transferase 0.474 0.023 9 0.595 0.091 7 0.509 0.017
 mir‑3615 Gamma‑glutamyl transferase 0.476 0.028 17 −0.002 0.997 10 0.046 0.817
 mir‑24‑1 Left inferior frontal triangular gyrus 0.548 0.006 16 0.547 0.068 9 0.060 0.768
 mir‑136 Left inferior frontal triangular gyrus 0.567 0.005 7 0.211 0.708 5 −0.108 0.753
 mir‑1976 Left inferior frontal triangular gyrus 0.531 0.009 9 −0.069 0.887 7 −0.327 0.307
 mir‑320b‑2 Left ventral diencephalon 0.930 0.002 17 −0.606 0.213 10 −0.229 0.311
 miR‑301a‑3p Letter fluency score 0.732 0.025 6 0.797 0.055 4 0.480 0.077
 mir‑320b‑2 Letter fluency score 0.771 0.032 17 −0.396 0.371 9 −0.467 0.065
 miR‑660‑5p Letter fluency score 0.602 0.040 6 0.700 0.114 4 0.753 0.001
 mir‑30a Right anterior collateral transverse sulcus 0.467 0.026 17 0.080 0.819 10 −0.240 0.292
 miR‑301a‑3p Right anterior collateral transverse sulcus 0.845 0.005 6 0.652 0.152 5 0.728 0.002
 mir‑92b Right cingulomarginal sulcus 0.547 0.037 17 0.209 0.524 10 0.390 0.019
 mir‑24‑1 Right pars opercularis 0.441 0.037 16 −0.009 0.983 9 −0.099 0.655
 mir‑136 Right pars opercularis 0.447 0.034 7 −0.556 0.496 5 −0.287 0.443
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cluster whose associations were not evident in the initial 
Pearson correlation analysis contained Tier A molecule 
mir-92b and several brain regions (left and right cingu-
lomarginal sulci, left and right inferior frontal lobe areas, 
and the anterior corpus callosum). Notably, this cluster 
was located adjacent to another cluster containing Let-
ter Fluency Score, as well as miR-660-5p (Fig.  3). mir-
92b has been shown to be abundant in the developing 
cortex and to regulate the development of intermediate 
cortical progenitor cells [39]. While our AUD subjects 
were adults and thus not undergoing large scale cortical 
neurogenesis, these data nevertheless support a possi-
ble role for mir-92b in mediating brain damage resulting 
from AUD that will need further exploration because of 
the functional implications of the aforementioned brain 
areas regarding speech and language processing.
Gene expression signatures related to brain-specific 
expression profiles
Although a peripheral biomarker can be useful from 
a purely diagnostic or correlative perspective, we also 
sought to obtain additional insight into the potential 
relevance of our serum-based miRNA data for provid-
ing information about brain miRNA levels. To begin 
to address this, we determined possible tissue origins 
for miRNAs of interest by performing comprehen-
sive miRNA profiling on 15 distinct tissues and serum 
derived from three normal adolescent (P35) male rats. 
Tissue-specific profiles were generated on miRNAs from 
Tiers A, B and C. These data were normalized to the total 
miRNA levels in each tissue and compared to brain hem-
isphere levels in these same animals by hierarchical clus-
ter analysis to discern meaningful patterns across tissues 
(Fig. 4). The levels of expression in the serum were also 
displayed for the same miRNAs.
Using this method, we found that most of the miR-
NAs of interest were present in the whole brain at mod-
erate to high levels (except for mir-378a). Moreover, at 
least 5 of the miRNAs were grouped together follow-
ing this analysis and appeared to be brain-enriched 
(mir-96-5p, mir-96, mir-92b, mir-127, mir-136; Fig.  4, 
upper). Notably, however, several of these were also 
enriched in muscle, spleen, skin, stomach, or testes, 
though in different combinations. Interestingly, mir-
92b showed particular enrichment in brain and lung, 
which was not a common pattern among any other 
miRNAs. Most of the miRNAs in Fig. 4 were also highly 
expressed in the serum of normal adolescent rats, with 
the exception of mir-96, miR-96-5p, and miR-150-3p. 
Also of note was the fact that all of the miRNAs were 
completely conserved in their mature forms between 
rat and humans, although some nucleotide differences 
were present in the immature stem-loop sequences 
(Fig. 4, right). Thus, based on the cross-tissue analysis 
in rat, we are confident that at least some of the miR-
NAs in the human serum could be derived from the 
brain, although we cannot rule out other contributing 
sources without additional studies.
Table 5 Tier C variables significantly correlated with any miRNA in AUD subjects (FDR < 0.05)
Pearson correlation analysis of miRNA expression levels in AUD subjects reveal significant relationships between specific miRNA expression levels and other medical, 
drinking and neuroimaging variables that were significantly different in AUD subjects
R Pearson correlation coefficient, P-value uncorrected P value for correlation, BH FDR Benjamini-Hochberg False Discovery Rate corrected P value, N number of pairs 
used in the calculation
miRNA Variable AUD Ctrl All
R P-value BH FDR N R P-value BH FDR N R P-value BH FDR
In all miRNAs
 let‑7a‑5p Heavy drinking days last week 0.846 3.1E−06 0.034 9
 mir‑93 Heavy drinking days last week 0.869 1.3E−07 0.006 10
 miR‑139‑5p Heavy drinking days last week 0.992 2.2E−06 0.048 4
 miR‑1180‑3p Heavy drinking days last week 0.975 5.07E−06 0.043 3
 miR‑584‑5p Left lateral fusiform gyrus 0.804 4.03E−06 0.040 17 −0.524 0.264 1 10 0.421 0.011 0.541
 miR‑16‑2‑3p Left precuneus 0.977 4.38E−06 0.040 8 −0.045 0.925 0.995 7 0.540 0.013 0.577
 mir‑5010 Left subparietal sulcus 0.934 4.22E−07 0.014 12 0.729 0.026 0.988 7 0.807 7.80E−07 0.038
 miR‑4433‑3p Right insular white matter 0.948 2.59E−06 0.047 10 0.004 0.992 1 8 0.309 0.157 1
 miR‑4433b‑5p Right insular white matter 0.948 2.59E−06 0.047 10 0.004 0.992 1 8 0.309 0.157 1
 mir‑378a Right medial orbital olfactory sulcus 0.821 1.85E−06 0.046 17 −0.268 0.520 1 10 0.463 0.004 0.597
 miR‑150‑3p Right paracentral white matter 0.830 2.78E−06 0.034 16 0.724 0.015 0.616 8 0.702 4.61E−06 0.062
 miR‑192‑5p Right rostral anterior cingulate 0.813 2.74E−06 0.038 17 −0.123 0.751 0.993 10 0.469 0.004 0.356
 mir‑664 Systolic blood pressure 0.995 3.18E−08 0.003 8 −0.179 0.838 1 4 0.934 4.52E−07 0.044
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Systems level cross-paradigm analysis reveals a common 
theme: miRNAs and targets that regulate cellular 
development, cell growth and proliferation, and cell death 
and survival are the most consistently affected in AUD 
subjects and drinking models
In addition to the human serum miRNA profiling, we 
also utilized two other ethanol exposure paradigms in 
an attempt to corroborate ethanol-induced effects found 
in human serum. We first performed serum miRNA 
profiling using an in  vivo rat drinking model wherein 
adult rats were subjected to a 6.7  % ethanol (w/v) diet 
for 3  weeks. Exposures were either performed daily or 
3  days per week. Serum miRNA levels were measured 
and compared to those from pair-fed controls who 
received an isocaloric non-alcoholic liquid diet during 
the same binge periods. To these data we then added 
additional miRNA profiling data obtained from an 
in  vitro NS5 neural stem cell ethanol exposure model 
(400 mg/dL in the presence of FGF or TGFβ1 for 48 h) 
[40]. Because miRNAs have the capacity to modulate 
multiple gene targets and show cell context-dependent 
effects, we elected to perform a systems-level analysis 
rather than a screen for individual targets identified in 
our human studies. Thus, common molecular functions 
and biological networks were ascertained and com-
pared across paradigms rather than individual miRNAs. 
The cross-paradigm systems level analysis was accom-
plished using QIAGEN Ingenuity® IPA analysis using all 
Fig. 3 Variables and miRNAs delineate AUDs from controls. Hierarchical clustering of nominally significant clinical, neuropsychological and neuro‑
imaging data combined with miRNAs belonging to Tiers A and B. Clusters reveal relationships between specific serum miRNAs and brain volumes. 
Log normalized median scaled values are shown. L left, R right
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nominally significant miRNAs (p  <  0.1; see Additional 
file 1) from both the in vitro and in vivo ethanol expo-
sure paradigms and human serum miRNAs from Tiers A 
and B (Table 6). Surprisingly, we found that 3 of the top 5 
molecular functions represented in the altered miRNAs 
overlapped across these very different data sets: (1) Cel-
lular development, (2) Cell growth and proliferation, and 
(3) Cell death and survival. These results provide strong 
evidence that that alcohol induces global miRNA expres-
sion changes affecting these functions in the mature 
brain, and potentially in developing brain cells as well. 
All of these changes are detectable in serum.
We further extended our systems-level analysis beyond 
the miRNAs themselves, to explore possible functional 
predictions in experimentally-confirmed or highly-pre-
dicted genes that are targeted by the miRNA molecules 
identified from human serum (Fig. 5). Inspection of the 
networks and nodes formed by the secondary (miRNA-
gene) and tertiary (gene–gene) relationships revealed a 
few key hub molecules at the intersection of the common 
gene targets and networks affected by the miRNAs. The 
most striking of these hub molecules were p53 and tumor 
necrosis factor (TNF), which are critical mediators of cell 
cycle progression, DNA repair and apoptosis. Thus, these 
molecules may exert key influences over the miRNA-
induced changes resulting from alcohol exposure.
Conclusion
In this study, we examined the potential for serum 
 miRNAs to serve as biomarkers of alcohol-related 
structural and functional CNS damage in human sub-
jects. This diverse and largely uncharacterized class of 
genomic regulators has the capacity to enact change on a 
global scale. Harnessing several lines of inquiry, our work 
integrated medical, neuropsychological, neuroimaging 
and alcohol consumption measures with miRNA expres-
sion levels to probe for informative markers of ARBD.
Because we focused on younger individuals with AUDs, 
our work also adds to a small, but growing body of lit-
erature surrounding ARBD in young adults. Although we 
found significant group differences in our AUD subjects’ 
Letter Fluency test scores, we note that overall, AUD sub-
jects did not show signs of cognitive impairment. This 
supports the notion that administering such tests on 
younger individuals may not prove to be as informative 
as they are for older chronic alcoholics with more pro-
nounced deficits.
On the other hand, we observed more robust differ-
ences between AUD subjects and controls when we 
examined specific brain volumes. Furthermore, although 
many of our observations were similar to those reported 
previously in older alcoholic subjects, we observed these 
effects on younger subjects, with a significantly shorter 
history of heavy drinking. The importance of assessing 
alcohol-related brain damage in younger AUD subjects, 
even in the absence of obvious functional deficits, is only 
recently being explored [Reviewed in 41] and clearly 
merits further investigation. Regardless, however, such 
an approach is not feasible on a broad scale for monitor-
ing due to its prohibitive costs.
Fig. 4 Comparison with tissue miRNA profiles suggests origins for specific serum miRNAs. Pooled miRNAs purified from tissues of 3 male P35 
normal rats were compared to expression levels measured in whole brain hemispheres. Rattus norgvegicus expression levels for specific miRNAs 
belonging to Tiers A, B and C were clustered to determine microRNAs which are enriched in the brain compared to 14 other tissues. For relative 
comparisons, the levels of these miRNAs in the serum are also shown, and the number of base differences between the rat and human miRNA 
sequences are shown for both the fully mature and stem‑loop forms
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In contrast, our results have identified potential 
miRNA biomarkers in the serum which ultimately could 
serve as practical, sensitive and reliable indicators of neu-
rocognitive decline and ARBD. At this point at least, in 
the case of Tiers A and B microRNAs, we also found that 
the miRNA changes were observable using two comple-
mentary high-throughput quantification technologies. To 
be ideal, however, it would be helpful to know the time 
course over which such biomarker profiles develop, and 
whether such profiles were reversible or not as a result of 
abstinence from alcohol.
There are some limitations worth noting in the present 
study. First, the systems-level approach that we used to 
evaluate cellular functions takes into account the inher-
ently pleiotropic nature of miRNAs. These miRNAs 
have the capacity to regulate hundreds of genes within 
any given cell. Thus, determining precise mechanisms 
of action clearly requires additional investigation. Fur-
ther, interpretation of miRNA-mediated changes in 
gene expression also requires a combinatorial approach 
wherein they are analyzed in the context of accessi-
ble messenger RNA targets and the presence of other 
miRNA molecules that can synergize more drastic 
changes in gene expression.
In spite of these limitations, we have shown that alco-
hol acts on similar cellular functions: cell death and 
survival, cellular development and cell growth and pro-
liferation across different ethanol exposure paradigms. 
Our analysis has revealed perturbation of biologically 
plausible pathways that have previously been shown to 
be altered in response to ethanol exposure in both pre-
natal and postnatal settings. Thus, although our results 
are by no means definitive, they highlight the tremendous 
potential of miRNAs as non-invasive ARBD biomarkers.
Fig. 5 p53 is highly involved in AUD‑related miRNA changes. Ingenuity IPA analysis of ethanol up‑ (red) or down‑ (green) regulated miRNAs in Tiers 
A & B show enrichment of molecules implicated in p53‑related pathways. Molecular activity prediction shows a general inhibition of this pathway 
as a result of miRNA expression changes. ADAMTS8 ADAM metallopeptidase with thrombospondin 8, CEP120 centrosomal protein 120, Cg Choriog‑
onadotropin, CHSY3 chondroitin sulfate synthase 3, Gulo gulonolactone L‑oxidase, MRPS33 mitochondrial ribosomal protein S33, NPEPL1 amin‑
opeptidase‑like 1, PAK1 p‑21 protein‑activated kinase 1, PNPLA3 patatin‑like phospholipase domain‑containing protein 3, PROSC proline synthetase, 
SCYL3 SCY1‑like 3, SLC2A8 and 10A3, solute carriers 2A8 and 10A3, TMEM163 transmembrane protein 163, TNF tumor necrosis factor, XKR8 XK, Kell 
blood group complex subunit‑related family 8
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Methods
Subject selection and exclusion
All research performed on human subjects was approved 
by the Institutional Review Boards (IRBs) of SUNY 
Upstate Medical University and Crouse Hospital. Sub-
jects were recruited from the Syracuse, New York area. 
Exclusion criteria included: age less than 18 or greater 
than 60, weight greater than 270 lbs, pregnancy, a his-
tory of head injury with loss of consciousness, co-morbid 
drug abuse (except for cigarette smoking) or co-morbid 
medical conditions including diabetes, cancer, hepatitis 
C, neurological diseases (such as seizure disorder) and 
major mental illness (except for anxiety and depression). 
All subjects had to agree to an MRI scan so patients with 
claustrophobia or metal implants of any kind were also 
excluded.
The Structured Clinical Interview for DSM-IV (SCID) 
[42] and Semi-Structured Assessment for the Genetics 
of Alcoholism version IV (SSAGA-IV) [43] were admin-
istered by a psychiatrist or psychiatric nurse practitioner 
to subjects to establish a diagnosis of DSM-IV alcohol 
dependence (AD) or alcohol abuse (AA), using widely-
accepted criteria. The interview also collected demo-
graphics, past medical history as well as alcohol and 
tobacco use data. A total of 30 subjects participated in 
this study. Controls were selected from individuals who 
had not consumed a standard drink in the past month 
and who had never consumed more than two drinks at 
any time in their life. The final group of subjects were 
composed of 10 non-drinking controls and 20 currently 
diagnosed with AUDs, 16 with AD and 4 with AA.
Medical, neuropsychological and neuroimaging 
assessments
Medical, neuropsychological and neuroimaging assess-
ments were performed as described in Hicks et  al. [3]. 
Briefly, after obtaining informed consent, subjects were 
screened using a dipstick urine test for drug abuse and a 
breath alcohol test. Subjects then underwent a brief neu-
rological examination which screened for obvious signs 
of cerebellar damage (a common occurrence in chronic 
AUD subjects). Standardized neuropsychological tests 
were administered by trained examiners to evaluate cog-
nitive function and included the Wechsler Abbreviated 
Scale of Intelligence (WASI), the Wechsler Memory Scale 
(WMS) and selected scales from the Delis-Kaplan Execu-
tive Function System [14], including trail-making tasks 
and word generation tasks such as letter fluency and cat-
egory fluency tests.
Neuroimaging analysis was performed following a 
structural head MRI series obtained using a 1.5 T Philips 
Gyroscan scanner. Subjects were scanned in the sagittal 
plane using the following T-1 weighted inversion recov-
ery 3D pulse sequence: TE  =  4.6  ms; TR  =  20  ms; 2 
repetitions; matrix size 256 ×  154 pixels; FOV 24  cm2; 
multishot = 32 repeats; TFE shortest possible pre-inver-
sion time = 394 ms and 1.5 mm slice thickness.
We initially used the MRI data to screen our AUD sub-
jects for evidence of neurodegenerative changes mani-
fested as sulcal widening (a consequence of gray matter 
loss). To complete this process, skull-stripping and 3-D 
brain reconstruction were completed using MRIcro [44] 
and the built-in brain extraction tool [45]. The recon-
structed volumes were then imported into Fiji [46] and 
subjected to both moments [18] and triangle [19] auto-
thresholding algorithms to quantify total sulcal area 
in the dorsal brain surface. These sulcal areas were 
expressed as a percentage of the total dorsal surface area.
Based on the initial positive findings from our dorsal 
surface analysis, we completed a more comprehensive 
cortical reconstruction and volumetric segmentation of 
the MRI images using the semi-automated FreeSurfer 
image analysis suite (http://surfer.nmr.mgh.harvard.edu) 
[Reviewed in 20]. Measurements were made of parcel-
lated volumes of more than 360 cortical and subcortical 
brain structures, including cortical gray matter, white 
matter, gyri and sulci. To control for overall brain shrink-
age generally observed in brains of subjects with AUDs, 
volumes were normalized relative to the whole brain 
volume. All volumetric comparisons made in this study 
were between normalized whole brain ratios of specific 
regions.
For the serum miRNA studies, blood samples were col-
lected into 10 cc BD Vacutainer® SST™ Serum Separation 
Tubes, inverted several times, allowed to coagulate, then 
centrifuged according to manufacturer’s instructions. 
Serum samples were then frozen at −80 °C until needed 
for miRNA purification. To obtain the miRNA, the serum 
was centrifuged at 3000  rpm for 5  min and the cleared 
cell-free supernatant processed using the miRNeasy kit 
(Qiagen). An additional blood sample from each subject 
was also collected for routine laboratory measures that 
included (1) serum AST, ALT and GGT levels, (2) blood 
glucose levels, (3) differential white blood cell counts and 
(4) a complete blood cell count.
The combined medical, demographic, neuropsycho-
logical and neuroimaging data were first evaluated for 
equality of variances using a Fisher’s F ratio test. Notably, 
this use of the Fisher F test is a different use than what 
is determined in an analysis of variance F test for multi-
ple groups. In this report, group differences for variables 
with unequal variances were determined using a Welch’s 
T-test. Otherwise, group differences were evaluated 
using a Student’s T-test.
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Rat drinking models
Animals were cared for in accordance with protocols 
approved by the Committee for the Humane Use of 
Animals (CHUA) at SUNY Upstate Medical University. 
A total of 38 (20 male and 18 female) Long-Evans rats 
obtained from Harlan Labs were used in the drinking 
studies. These rats were housed in individual cages and 
exposed to a 12  h reverse light/dark cycle. Fresh food 
was provided to all rats at 10:00 am. The liquid diet was 
obtained from OpenSource Research Diets™. Through-
out the study duration, regular records of the rats’ body 
weights and ethanol (or control diet) consumption were 
maintained.
At postnatal day 29 rats were split into four groups 
(two treatment and two control groups). The first treat-
ment and control groups examined the effects of daily 
drinking. These groups consisted of 11 rats each (6 male, 
5 female). The treated rats were weaned onto an ad lib 
liquid ethanol-containing diet for 3  weeks, beginning 
in early adolescence and extending to early adulthood. 
Rats initiated the ethanol (ET) diet at a dose of 2.2 % v/v 
and were weaned up to 4.5  % v/v and finally 6.7  % v/v 
over a 3  day period. After this initial exposure, the rats 
received 6.7 % v/v liquid ethanol diet for three consecu-
tive weeks. These treated rats were matched with pair-fed 
(PF) controls based on gender and initial body weight 
and received aliquots of the control diet defined by the 
amount of food consumed by the corresponding paired 
ethanol-fed rat. Maltose replaced ethanol in the control 
pair-fed diet to match for caloric and nutritional con-
tent. The next treatment and control groups examined 
the effects of intermittent binge drinking. These groups 
consisted of 8 rats each (4 male, 4 female). The treated 
rats received 6.7 % v/v liquid ethanol diet for three con-
secutive days each week, followed by 4  days of ad lib 
solid rat chow pellets (Purina). The PF controls for this 
group received the isocaloric maltose diet for 3 days, fol-
lowed by 4 days of solid chow. After the 3 week ethanol 
exposure period, all rats in each group were euthanized 
with CO2 and blood was collected into BD Vacutainer® 
SST™ tubes for serum miRNA isolation and routine clini-
cal laboratory profiling, as described for the human sera. 
Analysis of blood tail vein samples from a separate cohort 
of rats treated with the same diet for 3 weeks indicated 
peak blood ethanol concentrations exceeding 300  mg/
dL in both male and female adolescent rats that occurred 
within 3 h of access to the alcohol-containing diet at the 
beginning of each dark phase.
Tissue miRNA profiling
To help determine the potential tissue origins of any can-
didate serum-based miRNA biomarkers, we performed a 
detailed analysis of miRNA levels in 15 different tissues 
and serum in a separate cohort of 3 untreated male Long 
Evans rats. These tissues included an entire brain hemi-
sphere, hindlimb muscle, lung, heart, kidney, thymus, 
pancreas, subcutaneous abdominal fat, stomach, testes, 
liver, skin, spleen, large intestine and small intestine. Tis-
sues were dissected and stored in RNAlater (Sigma), and 
subsequently homogenized prior to miRNA purification. 
Purified miRNAs from all three animals were pooled 
together to generate a specific miRNA profile for each 
tissue of origin, except for the brain hemispheres which 
were run individually.
Mouse neural stem cells
Ethanol exposures of mouse NSCs were performed as 
described in Hicks et  al. [4]. Briefly, eighteen 10  cm 
dishes coated with poly-l-ornithine hydrobromide and 
laminin (Sigma) were plated with 3.0  ×  106 cells and 
incubated for 24 h in a Euromed-N maintenance medium 
(Euroclone). Plates were then separated into 4 groups 
and exposed to different media for 48  h: maintenance 
media supplemented with 10  mg/ml FGF2 (Preprotech) 
(n  =  4) or TGFβ1 (R&D Systems) (n  =  5). In another 
set of dishes, 400  mg/dl of ethanol was added in each 
type of supplemented media (FGF2 + ethanol, n = 4 or 
TGFβ1 +  ethanol, n = 5). All dishes were placed inside 
airtight containers with either sterile water alone or with 
400  mg/dl ethanol to maintain constant concentration 
throughout the exposure period [42]. After the exposure, 
cells were harvested for miRNA purification.
Nucleic acid preparation and expression profiling
Serum miRNAs from both humans and rats were purified 
using the miRNeasy Serum/Plasma kit (Qiagen). MicroR-
NAs from NSCs and all rat tissues were extracted using 
the miRNeasy Mini kit (Qiagen). The yield, purity and 
size distribution of the miRNA samples were assessed 
using a Bioanalyzer Nano RNA Lab Chip (Agilent).
NSC and rat serum miRNA samples were hybridized to 
GeneChip miRNA 2.0 arrays (Affymetrix). Human serum 
miRNA samples were hybridized to GeneChip miRNA 
3.0 arrays (Affymetrix). RMA-normalized microarray 
data were analyzed using Partek Genomics Suite. For 
next-generation sequencing (NGS), human serum miR-
NAs and Rat tissue miRNA samples were used to prepare 
small RNA libraries using the TruSeq Small RNA Sam-
ple Prep kit (Illumina). Libraries were sequenced using a 
MiSeq Benchtop Sequencer (Illumina) and data uploaded 
into BaseSpace for initial QC and mapping.
FASTQ files were subsequently imported into Partek 
Flow and Strand NGS suites for analysis. Base calls below 
a phred score of 20 were trimmed. Reads were aligned to 
the human hg19 or rat Rn5 reference genomes using the 
Bowtie algorithm [47]. These were then quantified against 
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both miRBase and RefSeq transcript miRNA annota-
tions. Any miRNAs that were detected in fewer than five 
human subjects were discarded from further analysis. 
Raw miRNA counts were then normalized to the total 
number of miRNA reads per sample. Concentrations were 
expressed as a percentage of total miRNA reads. Notably, 
the described purification methods allowed sequencing 
of very pure miRNA samples, with more than 90 % of all 
reads in the sample attributed to miRNAs. All of the raw 
and processed microarray and RNA-sequencing data gen-
erated in this study have been deposited in the National 
Center for Biotechnology Information (NCBI) public 
Gene Expression Ominibus (GEO) database as SuperSer-
ies GSE71579 and are available for immediate download.
The appropriate test for group differences between 
AUD and control expression levels was determined using 
the Fisher’s F test to determine unequal variances. For 
miRNAs with equal variances between groups, the Stu-
dent’s T-test was used. If deemed unequal, the data for 
a specific miRNA was further tested for normality using 
the Shapiro–Wilk’s test. Group differences for miRNAs 
passing the normality test (p  >  0.05) were determined 
using a Welch’s T-test while those that failed the normal-
ity test were compared using the Mann–Whitney test. 
Filtered human serum miRNAs were then designated 
into two different tiers depending on whether group dif-
ferences and directional changes in expression levels 
were concordant with miRNA array data. Notably, these 
differences were not subjected to multiple testing correc-
tion because one of our main goals was to uncover quan-
titative relationships between variables that would clearly 
have been discarded had we used a stringent FDR correc-
tion for the between-group comparisons. The differences 
that are reported were designated as “nominally signifi-
cant” for this reason. Lists of all differences  in miRNA 
levels (p < 0.10) in the rat drinking paradigms and mouse 
neural stem cell cultures was also generated for compari-
son with the human data (Additional file 1). 
Correlation, clustering and systems-level analyses
Pearson correlation matrices were generated for AUD, 
Control and combined subject groups. Comparisons 
were made between the combined medical, neuropsycho-
logical and neuroimaging variables and the normalized 
serum miRNA levels for each individual. For matrices 
composed of AUD subjects, we also included indices of 
drinking consumption for comparison with miRNA lev-
els. The significance of these correlations was calculated 
using an R to T transformation and adjusted for multiple 
comparisons with the Benjamini-Hochberg False Discov-
ery Rate (FDR) correction algorithm.
We combined all miRNAs from Tiers A and B  with 
the nominally significant medical, neuroimaging and 
neuropsychological variables for hierarchical cluster-
ing. This was performed using the Microarray Experi-
ment Viewer 4 (MEV4) software (TIGR, Johns Hopkins; 
http://www.tm4.org/mev.html) [38]. Data were scaled by 
mean-centering then division by the standard deviation 
of each variable. Clusters were created using the average 
linkage and the Pearson distance metric. The cross-tissue 
miRNA data from the rats were aligned and quantified as 
previously described. RPM normalized expression lev-
els were then imported into MEV software, subjected to 
per-miRNA median centering and log2 transformation 
and used for clustering analysis to compare the expression 
levels across the 15 tissues for microRNAs in Tiers A, B 
(Table 5).
The miRNAs in Tiers A and B were analyzed using the 
Core Analysis workflow of QIAGEN Ingenuity® IPA plat-
form’s Core Analysis package to identify enriched gene 
networks considering only relationships that were highly 
predicted or experimentally observed. The top molecu-
lar and cellular functions identified in the AUD subjects, 
drinking rats, and in  vitro studies of mouse NSCs were 
then compared.
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